Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epoetin alfa DT · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Epoetin alfa DT | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Epoetin alfa DT | DRUG | Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL |
Inclusion Criteria: - ≥ 18 years of age - Receiving hemodialysis or peritoneal dialysis - Baseline Hb between 11.0 g/dL and 13.0 g/dL - Currently receiving Epoetin alfa RB ie. EPOGEN or PROCRIT - Transferrin saturation (Tsat) \>15.0% Exclusion Criteria: - Currently receiving or ever received treatme...
Top 20 of 28 competitors
Epoetin alfa DT is an investigational small molecule developed by Amgen Inc. (ticker AMGN) for chronic kidney disease in the nephrology therapeutic area. It is designed as an EPOR agonist and has been studied in a Phase 3 trial. It is not described as an approved product.
Epoetin alfa DT is being developed for use in chronic kidney disease. Its clinical program includes a Phase 3 study in dialysis subjects with chronic kidney disease. The drug is an EPOR agonist small molecule from Amgen Inc. (AMGN).
Epoetin alfa DT targets EPOR, the erythropoietin receptor. It acts as an agonist at this receptor. EPOR agonism is the mechanism described for this small molecule in its development for chronic kidney disease by Amgen Inc. (AMGN).
Epoetin alfa DT is developed by Amgen Inc., which trades under the ticker AMGN. Amgen is the company associated with this EPOR agonist small molecule for chronic kidney disease.
Epoetin alfa DT is in Phase 3 development. It is an investigational drug and is not described as FDA approved. The Phase 3 program includes one completed trial in chronic kidney disease.
Epoetin alfa DT has been studied in the Phase 3 trial NCT00156949, titled EPO Deep Tank in Dialysis Subjects. That trial enrolled 580 participants with chronic kidney disease, was uncontrolled, and is now completed. No active trials are listed.